{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:40:26Z","timestamp":1790739626028,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T00:00:00Z","timestamp":1390435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2013.552","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T16:04:25Z","timestamp":1390493065000},"page":"e1013-e1013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles\u2019 heel in mantle cell lymphoma"],"prefix":"10.1038","volume":"5","author":[{"given":"M A","family":"Dengler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Weilbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gutekunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Staiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"V\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W E","family":"Aulitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"van der Kuip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,23]]},"reference":[{"key":"BFcddis2013552_CR1","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrc2230","volume":"7","author":"P Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E . Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750\u2013762.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2013552_CR2","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E . Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416\u20133423.","journal-title":"J Clin Invest"},{"key":"BFcddis2013552_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P P\u00e9rez-Gal\u00e1n","year":"2011","unstructured":"P\u00e9rez-Gal\u00e1n P, Dreyling M, Wiestner A . Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26\u201338.","journal-title":"Blood"},{"key":"BFcddis2013552_CR4","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","volume":"23","author":"V Fern\u00e0ndez","year":"2005","unstructured":"Fern\u00e0ndez V, Hartmann E, Ott G, Campo E, Rosenwald A . Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23: 6364\u20136369.","journal-title":"J Clin Oncol"},{"key":"BFcddis2013552_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nrd3937","volume":"12","author":"RM Young","year":"2013","unstructured":"Young RM, Staudt LM . Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229\u2013243.","journal-title":"Nat Rev Drug Discov"},{"key":"BFcddis2013552_CR6","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","volume":"111","author":"JD Col","year":"2008","unstructured":"Col JD, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008; 111: 5142\u20135151.","journal-title":"Blood"},{"key":"BFcddis2013552_CR7","first-page":"8226","volume":"63","author":"N Mart\u00ednez","year":"2003","unstructured":"Mart\u00ednez N, Camacho FI, Algara P, Rodr\u00edguez A, Dopazo A, Ru\u00edz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226\u20138232.","journal-title":"Cancer Res"},{"key":"BFcddis2013552_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/1042819031000151112","volume":"45","author":"MJ Rummel","year":"2004","unstructured":"Rummel MJ, de Vos S, Hoelzer D, Koeffler HP, Hofmann W-K . Altered apoptosis pathways in mantle cell lymphoma. Leuk Lymphoma 2004; 45: 49\u201354.","journal-title":"Leuk Lymphoma"},{"key":"BFcddis2013552_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","volume":"24","author":"H Tagawa","year":"2005","unstructured":"Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348\u20131358.","journal-title":"Oncogene"},{"key":"BFcddis2013552_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507\u2013516.","journal-title":"N Engl J Med"},{"key":"BFcddis2013552_CR11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.leukres.2012.02.010","volume":"36","author":"A Kim","year":"2012","unstructured":"Kim A, Park S, Lee J-E, Jang W-S, Lee S-J, Kang HJ et al. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leuk Res 2012; 36: 912\u2013920.","journal-title":"Leuk Res"},{"key":"BFcddis2013552_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP . Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011; 11: 239\u2013253.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFcddis2013552_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P P\u00e9rez-Gal\u00e1n","year":"2006","unstructured":"P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257\u2013264.","journal-title":"Blood"},{"key":"BFcddis2013552_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddis2013552_CR15","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","volume":"26","author":"J Adams","year":"2007","unstructured":"Adams J, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324\u20131337.","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"BFcddis2013552_CR16","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1038\/onc.2009.46","volume":"27","author":"C Ploner","year":"2008","unstructured":"Ploner C, Kofler R, Villunger A . Noxa: at the tip of the balance between life and death. Oncogene 2008; 27 (Suppl 1): S84\u2013S92.","journal-title":"Oncogene"},{"key":"BFcddis2013552_CR17","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3324\/haematol.2010.022368","volume":"95","author":"M Baou","year":"2010","unstructured":"Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R et al. Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica 2010; 95: 1510\u20131518.","journal-title":"Haematologica"},{"key":"BFcddis2013552_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.celrep.2013.02.014","volume":"3","author":"K Brinkmann","year":"2013","unstructured":"Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P et al. Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep 2013; 3: 881\u2013891.","journal-title":"Cell Rep"},{"key":"BFcddis2013552_CR19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/0008-5472.CAN-12-2876","volume":"73","author":"M Gutekunst","year":"2013","unstructured":"Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S et al. Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4. Cancer Res 2013; 73: 1460\u20131469.","journal-title":"Cancer Res"},{"key":"BFcddis2013552_CR20","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1182\/blood-2011-09-378877","volume":"119","author":"FM Wensveen","year":"2012","unstructured":"Wensveen FM, Derks IAM, van Gisbergen KPJM, de Bruin AM, Meijers JCM, Yigittop H et al. BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. Blood 2012; 119: 1440\u20131449.","journal-title":"Blood"},{"key":"BFcddis2013552_CR21","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/blood-2010-06-288027","volume":"117","author":"J Bretz","year":"2011","unstructured":"Bretz J, Garcia J, Huang X, Kang L, Zhang Y, Toellner K-M et al. Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors. Blood 2011; 117: 2179\u20132188.","journal-title":"Blood"},{"key":"BFcddis2013552_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603\u2013607.","journal-title":"Nature"},{"key":"BFcddis2013552_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.beha.2012.04.007","volume":"25","author":"B Holkova","year":"2012","unstructured":"Holkova B, Grant S . Proteasome inhibitors in mantle cell lymphoma. Best Pract Res Clin Haematol 2012; 25: 133\u2013141.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFcddis2013552_CR24","doi-asserted-by":"publisher","first-page":"e33738","DOI":"10.1371\/journal.pone.0033738","volume":"7","author":"P Gelebart","year":"2012","unstructured":"Gelebart P, Zak Z, Anand M, Belch A, Lai R . Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PloS One 2012; 7: e33738.","journal-title":"PloS One"},{"key":"BFcddis2013552_CR25","doi-asserted-by":"publisher","first-page":"e19198","DOI":"10.1371\/journal.pone.0019198","volume":"6","author":"M Gutekunst","year":"2011","unstructured":"Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J et al. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PloS One 2011; 6: e19198.","journal-title":"PloS One"},{"key":"BFcddis2013552_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/sj.onc.1210672","volume":"27","author":"K Kurata","year":"2008","unstructured":"Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T . Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells. Oncogene 2008; 27: 741\u2013754.","journal-title":"Oncogene"},{"key":"BFcddis2013552_CR27","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1074\/jbc.M406661200","volume":"280","author":"M Flinterman","year":"2005","unstructured":"Flinterman M, Guelen L, Ezzati-Nik S, Killick R, Melino G, Tominaga K et al. E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem 2005; 280: 5945\u20135959.","journal-title":"J Biol Chem"},{"key":"BFcddis2013552_CR28","doi-asserted-by":"publisher","first-page":"8627","DOI":"10.1074\/jbc.M312866200","volume":"279","author":"T Hershko","year":"2004","unstructured":"Hershko T, Ginsberg D . Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004; 279: 8627\u20138634.","journal-title":"J Biol Chem"},{"key":"BFcddis2013552_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1593\/neo.07589","volume":"9","author":"Y Mei","year":"2007","unstructured":"Mei Y, Xie C, Xie W, Tian X, Li M, Wu M . Noxa\/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. Neoplasia 2007; 9: 871\u2013881.","journal-title":"Neoplasia"},{"key":"BFcddis2013552_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.12206","volume":"161","author":"G Dasmahapatra","year":"2013","unstructured":"Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S . The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013; 161: 43\u201356.","journal-title":"Br J Haematol"},{"key":"BFcddis2013552_CR31","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/sj.leu.2404528","volume":"21","author":"P Bonvini","year":"2007","unstructured":"Bonvini P, Zorzi E, Basso G, Rosolen A . Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007; 21: 838\u2013842.","journal-title":"Leukemia"},{"key":"BFcddis2013552_CR32","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/0008-5472.CAN-05-3018","volume":"66","author":"F Vega","year":"2006","unstructured":"Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase\u2013positive anaplastic large cell lymphoma. Cancer Res 2006; 66: 6589\u20136597.","journal-title":"Cancer Res"},{"key":"BFcddis2013552_CR33","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1210\/jc.2005-2472","volume":"91","author":"CS Mitsiades","year":"2006","unstructured":"Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006; 91: 4013\u20134021.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFcddis2013552_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/RLU.0b013e31824c5f24","volume":"37","author":"D Putzer","year":"2012","unstructured":"Putzer D, Gabriel M, Kroiss A, Madleitner R, Eisterer W, Kendler D et al. First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. Clin Nucl Med 2012; 37: 539\u2013544.","journal-title":"Clin Nucl Med"},{"key":"BFcddis2013552_CR35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732\u2013736.","journal-title":"Nature"},{"key":"BFcddis2013552_CR36","doi-asserted-by":"publisher","first-page":"e47298","DOI":"10.1371\/journal.pone.0047298","volume":"7","author":"S Wei","year":"2012","unstructured":"Wei S, Chu P-C, Chuang H-C, Hung W-C, Kulp SK, Chen C-S . Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent. PLoS One 2012; 7: e47298.","journal-title":"PLoS One"},{"key":"BFcddis2013552_CR37","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1158\/1078-0432.CCR-09-1592","volume":"16","author":"L Jia","year":"2010","unstructured":"Jia L, Yang J, Hao X, Zheng M, He H, Xiong X et al. Validation of SAG\/RBX2\/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin Cancer Res 2010; 16: 814\u2013824.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013552_CR38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/fon.10.11","volume":"6","author":"R Flavin","year":"2010","unstructured":"Flavin R, Peluso S, Nguyen PL, Loda M . Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol Lond Engl 2010; 6: 551\u2013562.","journal-title":"Future Oncol Lond Engl"},{"key":"BFcddis2013552_CR39","doi-asserted-by":"publisher","first-page":"30540","DOI":"10.1074\/jbc.M405061200","volume":"279","author":"LM Knowles","year":"2004","unstructured":"Knowles LM, Axelrod F, Browne CD, Smith JW . A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 2004; 279: 30540\u201330545.","journal-title":"J Biol Chem"},{"key":"BFcddis2013552_CR40","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"MA Milhollen","year":"2010","unstructured":"Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-\u03baB\u2013dependent lymphoma. Blood 2010; 116: 1515\u20131523.","journal-title":"Blood"},{"key":"BFcddis2013552_CR41","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","volume":"115","author":"RT Swords","year":"2010","unstructured":"Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796\u20133800.","journal-title":"Blood"},{"key":"BFcddis2013552_CR42","doi-asserted-by":"publisher","first-page":"e25139","DOI":"10.1371\/journal.pone.0025139","volume":"6","author":"MA Dengler","year":"2011","unstructured":"Dengler MA, Staiger AM, Gutekunst M, Hofmann U, Doszczak M, Scheurich P et al. Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. PLoS One 2011; 6: e25139.","journal-title":"PLoS One"},{"key":"BFcddis2013552_CR43","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood.V98.5.1532","volume":"98","author":"H Kuip","year":"2001","unstructured":"Kuip H, van der, Goetz AW, Miething C, Duyster J, Aulitzky WE . Adhesion to fibronectin selectively protects Bcr-Abl+cells from DNA damage\u2013induced apoptosis. Blood 2001; 98: 1532\u20131541.","journal-title":"Blood"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis2013552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis2013552","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2013552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:28:47Z","timestamp":1672961327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2013552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1]]}},"alternative-id":["BFcddis2013552"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2013.552","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,23]]},"assertion":[{"value":"14 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}